This podcast presents an interview with Dr. John Kellie, an Investigator in the Bioanalytical Sciences and Toxicokinetics group at GlaxoSmithKline, and a speaker in the Characterization of Biotherapeutics meeting at the 11th Annual PEGS Boston. John explains how next-generation analytical technologies are being used to characterize circulating ADC species, and how these findings support the development of safe and effective antibody-drug conjugate therapeutics.

To learn more, visit http://www.PEGSummit.com/Biotherapeutics-Characterization